USIL Therapeutics S.A : Radiological and Nuclear Risks: What’s New Since Chernobyl in Protecting Against Acute Radiation Syndrome?

Oct 1, 2026 — 03:15 pm - 4:00 PM
Spotlight Stage

Speakers:
Valentin WIEDLING
USIL Therapeutics, registered in Luxembourg, is developing the first field-deployable, multi-organ radiation treatment. UT-241 is an intramuscular autoinjector for self- or buddy-administration before or after exposure, on a platform already qualified and fielded across the alliance. UT-242, an intravenous formulation for sustained treatment at a field hospital.

Sponsored by